Inhibition of histone deacetylase (HDAC) has been implicated to modulate transcription and to induce apoptosis or differentiation in cancer cells. However, screening of compounds for HDAC inhibition has been difficult due to the lack of convenient tools for analyzing HDAC activity. The new HDAC Inhibitor Drug Screening Kit provides a fast, fluorescence-based method that eliminates radioactivity, extractions, or chromatography, as used in traditional assays. The new procedure requires only two easy steps, both performed on the same microtiter plate. First, your inhibitor candidates are mixed with HeLa Nuclear Extract and HDAC fluorometric substrate, which comprises an acetylated lysine side chain. Deacetylation of the substrate sensitizes the substrate, so that, in the second step, treatment with the Lysine Developer produces a fluorophore. The fluorophore can be easily analyzed using a fluorescence plate reader or a fluorometer. The assay is well suited for high throughput screening applications.
Sample Type:
Cell and Tissue lysates, culture media, urine, plasma and serum, as well as many other biological fluids.
Intended Use:
Screening of compounds for HDAC inhibition by analyzing HDAC activity.
Specificity:
Mammalian
Kit Componants:
HDAC substrate (4mM), 1x500ul/ml
10X HDAC assay buffer, 1x1ml
Lysine Developer, 1x1ml
HDAC Inhibitor (1mM), 1x10ul
HeLa nuclear extract, 1x200ul
Storage and Stability:
Store liquid at -20 degrees C. Stable for 6 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Quick Search
Products 
